Asenapine Tablet
Product Images NDC 51991-358

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Asenapine (NDC 51991-358). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Breckenridge Pharmaceutical, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Asenapine 01)

Chemical structure of asenapine maleate, showing the molecular configuration including chlorine, oxygen, nitrogen atoms, and carboxylic acid groups.*

FDA Label Image

Figure 1 (Asenapine 02)

A chart showing the pharmacokinetic (PK) fold change and 90% confidence intervals for asenapine when administered with various CYP enzyme inhibitors or inducers. The variables shown include Cmax and AUC changes relative to reference for fluvoxamine, imipramine, paroxetine, cimetidine, carbamazepine, and valproate, indicating their effects on asenapine exposure.*

FDA Label Image

Figure 2 (Asenapine 03)

A pharmacokinetic fold change chart showing the impact of different CYP enzyme substrates and inhibitors (Paroxetine, Imipramine, Desipramine) on Cmax and AUC values. The x-axis represents fold change relative to reference, ranging from 0.5 to 2.5, with data points and 90% confidence intervals for each substrate/drug combination.*

FDA Label Image

Figure 3 (Asenapine 04)

A forest plot chart showing fold change and 90% confidence intervals for pharmacokinetic parameters (Cmax and AUC) of Asenapine in different populations, including varying degrees of renal and hepatic impairment, smokers, Japanese subjects, and pediatrics, each relative to a reference group.*

FDA Label Image

Figure 4 (Asenapine 05)

A Kaplan-Meier survival curve chart comparing Asenapine sublingual tablets with placebo over 225 days. The chart displays percent relapse-free survival on the y-axis and time in days on the x-axis, showing that placebo group relapses at a higher rate than the Asenapine group over time. The number of patients at risk at various intervals is listed below the x-axis.*

FDA Label Image

Figure 5 (Asenapine 06)

A line graph comparing the percent of patients achieving relapse status over time (days) between Asenapine sublingual tablets and placebo. The x-axis represents time in days up to 240, and the y-axis shows the percent, with two lines: a solid line for Asenapine and a dotted line for placebo. The graph includes numbers at risk below for both groups over the study period.*

FDA Label Image

Figure A (Asenapine 07)

An instructional illustration showing a hand peeling back a blister pack section to remove a round tablet, indicating how to access individual sublingual tablets of Asenapine. The diagram highlights the action of separating the tablet from the packaging for administration.*

FDA Label Image

Figure B (Asenapine 08)

An instructional line drawing showing a hand lifting a sublingual tablet from its blister pack. The image highlights the action of peeling back the foil or plastic cover to access the tablet, commonly used for administering Asenapine sublingual tablets.*

FDA Label Image

Figure C (Asenapine 09)

An instructional illustration showing two hands with an arrow pointing to the center of a circular tablet in a blister pack. The image appears to demonstrate how to press a pill through the packaging foil.*

FDA Label Image

Figure D (Asenapine 10)

An illustration showing a close-up of a person placing a sublingual tablet under their tongue using their fingers, demonstrating the proper administration method for Asenapine sublingual tablets.*

FDA Label Image

Figure E (Asenapine 11)

An instructional illustration showing a crossed-out image of a fork, knife, spoon, and glass next to a label stating "10 minutes." This likely indicates a recommended waiting period related to food or drink before or after taking the medication.*

FDA Label Image

Principal Display Panel (10 mg Tablet Blister Pack Box)

Packaging label for Asenapine Sublingual Tablets 5 mg by Breckenridge Pharmaceutical, Inc. The label indicates the tablet is for sublingual use only and contains 60 unit-dose tablets (6x10). It includes warnings against splitting, cutting, crushing, chewing, or swallowing the tablet and instructions for use with illustrations. The label notes phenylalanine content and storage instructions.*

FDA Label Image

Principal Display Panel (2.5 mg Tablet Blister Pack Box)

Packaging label for Asenapine Sublingual Tablets 10 mg by Breckenridge Pharmaceutical, Inc. The label highlights sublingual tablets in unit-dose packaging (60 tablets, 6x10), with usage warnings and instructions for sublingual administration. Manufacturer is MSN Laboratories Private Limited, India. Contains phenylalanine 0.17 mg per tablet.*

FDA Label Image

Principal Display Panel (10 mg Tablet Blister Pack Box)

Packaging label for Asenapine Sublingual Tablets 5 mg in black cherry flavor by Breckenridge Pharmaceutical, Inc. The label indicates a unit-dose tablet form with 60 tablets per package (6x10). Instructions for sublingual administration and warnings are printed, along with the NDC 51991-358-60 and manufacturer details (MSN Laboratories, India).*

FDA Label Image

Asenapine 15

Packaging label for Asenapine Sublingual Tablets 10 mg by Breckenridge Pharmaceutical, Inc. The tablets are Black Cherry flavored, sublingual, and unit-dose packaged, with 60 tablets (6x10) per container. The label includes usage instructions, storage guidelines, and a warning about phenylalanine content for phenylketonurics.*

FDA Label Image

Asenapine 16

Asenapine Sublingual Tablets 2.5 mg in black cherry flavor. The label states the product is for sublingual use only and includes handling and storage instructions. The package contains 60 unit-dose tablets (6x10) and is labeled Rx only. Breckenridge Pharmaceutical, Inc. is the distributor, with manufacturing by Centaur Pharmaceuticals Pvt. Ltd.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.